FROST PHILLIP MD ET AL 4

4 · Cocrystal Pharma, Inc. · Filed Feb 9, 2026

AI-generated summary of this filing

Updated Feb 9, 2026

Cocrystal Pharma (COCP) 10% Owner Phillip Frost Buys 50,000 Shares

What Happened

Phillip Frost, reported as a 10% owner, acquired 50,000 shares of Cocrystal Pharma, Inc. (COCP) on Feb 6, 2026. The transaction was a purchase (reported as code P) at a weighted average price of $0.95 per share, totaling approximately $47,280. The Form 4 was filed on Feb 9, 2026.

Key Details

Transaction date: 2026-02-06; Form 4 filed: 2026-02-09 (timely filing).
Price: weighted average $0.95; individual purchase prices ranged from $0.8899 to $0.9880 (Footnote F1).
Total shares acquired: 50,000; approximate total value: $47,280.
Shares held after the transaction: not specified in the information provided in this summary.
Ownership/structure note (Footnote F2): the shares are held by Frost Gamma Investments Trust (Phillip Frost is trustee); Frost Gamma L.P. is sole beneficiary, with additional layers of entities. Dr. Frost disclaims beneficial ownership of the trust’s securities except to the extent of any pecuniary interest.
Footnote F3: references inclusion of shares issuable upon vesting of restricted stock units (may affect reported holdings).
Transaction type: open market or private purchase (the filing lists "open market or private purchase"); purchases are generally considered more informative than routine sales but do not, by themselves, indicate motive.

Context

This filing reports a direct purchase by a 10% owner via trust-controlled holdings; as a 10% owner (not an unrelated retail insider trade), reporting includes standard ownership disclaimers. No options were exercised, no awards or gifts reported in this transaction.

Form 4

Period: 2026-02-06

Director10% Owner

Transactions

Purchase
Common Stock
[F1][F2]
2026-02-06$0.95/sh+50,000$47,280→ 1,888,551 total(indirect: By Trust)

Holdings

Footnotes (3)

[F1]The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions ranging from $0.8899 to $0.9880, inclusive. The reporting person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares purchased at each separate price within the ranges set forth in the preceding sentence.
[F2]These shares are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
[F3]Includes shares of common stock issuable upon vesting of restricted stock units.

Signature

/s/ Phillip Frost, MD ET AL|2026-02-09

1 file